Evidence map›Paper›PMID 40772995›Full record

ArticleClinical & experimental metastasis2025

Cold atmospheric plasma-activated liquid inhibits peritoneal metastasis in drug-resistant ovarian cancer by targeting the epithelial-mesenchymal transition.

Jinren Liu, Xiangni Wang, Yixin Cui, Jiajia Lu, Zhirou He, Yulin Xu, Rongrong Li, Guimin Xu, Lingge Gao, Xiaolin Fan and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jinren LiuKey Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Medical Science Center, Xi'an Jiaotong University, Xi'an, China.
Xiangni WangKey Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Medical Science Center, Xi'an Jiaotong University, Xi'an, China.
Yixin CuiKey Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Medical Science Center, Xi'an Jiaotong University, Xi'an, China.
Jiajia LuKey Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Medical Science Center, Xi'an Jiaotong University, Xi'an, China.
Zhirou HeKey Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Medical Science Center, Xi'an Jiaotong University, Xi'an, China.
Yulin XuKey Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Medical Science Center, Xi'an Jiaotong University, Xi'an, China.
Rongrong LiKey Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Medical Science Center, Xi'an Jiaotong University, Xi'an, China.
Guimin XuSchool of Electronics and Control Engineering, Chang'an University, Xi'an, China.
Lingge GaoDepartment of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Xiaolin FanXi'an Key Laboratory of Toxicology and Biological Effects, Institute for Hygiene of Ordnance Industry, Xi'an, China.
Xili Wuthe Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xingmin ShiKey Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Medical Science Center, Xi'an Jiaotong University, Xi'an, China. shixingmin142@163.com.
Guanjun ZhangState Key Laboratory of Electrical Insulation and Power Equipment, Xi'an Jiaotong University, Xi'an, China. gjzhang@xjtu.edu.cn.

Funding

Fundamental Research Funds for the Central Universities xtr062024007Natural Science Basic Research Plan in Shaanxi Province 2024JC-YBMS-785Natural Science Basic Research Plan in Shaanxi Province 2025JC-YBMS-860Natural Science Foundation of Shaanxi Province 2022JQ-882Project of Independent Innovative Experiment for Postgraduates in medicine in Xi'an Jiaotong University YJSCX-2023-010Scientific Research Project of Shaanxi Provincial Administration of Traditional SZY-KJCYC-2023-084
6 · The paper itself

Abstract

Ovarian cancer remains a significant challenge in oncology due to its aggressive nature, late-stage diagnosis, and high rates of chemoresistance, particularly to platinum-based therapies like cisplatin. The epithelial-mesenchymal transition (EMT) is a key driver of ovarian cancer metastasis and drug resistance, highlighting the need for novel therapeutic strategies. Cold atmospheric plasma (CAP) and plasma-activated liquids (PAL), including plasma-activated medium (PAM) and saline (PAS), have emerged as promising anticancer agents, generating reactive oxygen and nitrogen species (RONS) that selectively target cancer cells. This study investigates the potential of PAL to inhibit the invasion and metastasis of cisplatin-resistant ovarian cancer cells and explores its synergistic effects with cisplatin. In vitro, PAM reduced proliferation, migration, and invasion of cisplatin-resistant ovarian cancer cells (A2780/DDP and SKOV3/DDP) while downregulating EMT-related proteins (N-cadherin, β-catenin, vimentin). H

Indexed as

Drug Resistance, NeoplasmEpithelial-Mesenchymal TransitionOvarian NeoplasmsPeritoneal NeoplasmsPlasma GasesAnimalsAntineoplastic AgentsCell Line, TumorCell MovementCell ProliferationCisplatinFemaleHumansMiceMice, NudeXenograft Model Antitumor AssaysAntineoplastic AgentsCisplatinPlasma GasesCisplatin resistanceCombination therapyEpithelial-mesenchymal transitionOvarian cancerPlasma-activated liquids

Identifiers

PMID40772995

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.